Jianfeng Group Lin2016 -031 (Announcement on Signing Letter of Intent for Foreign Investment of Subsidiates)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2016-031
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资签署合作意向书的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 交易简要内容:本公司控股子公司浙江尖峰药业有限公司近日与桂林商源植物制品有限公司签订了《合作意向书》,拟以北京慧宝源生物技术有限公司及其子公司为平台与其开展医药业务的合作。
l 本次交易不构成关联交易
l 本次交易不构成重大资产重组
l 本次签订的是合作意向书,是合作谈判的基础,该合作事项是否能够实现存在不确定性。
一、对外投资概述
(一)本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)近日与桂林商源植物制品有限公司(以下简称:桂林商源)签订了《合作意向书》,拟以现金出资,以增资扩股、受让股权的方式成为桂林商源子公司北京慧宝源生物技术有限公司(以下简称:北慧生物)的股东,以北慧生物及其子公司广西慧宝源医药科技有限公司(以下简称:广慧科技)为平台开展医药业务的合作。
(二)本次签订的是合作意向书,是合作谈判的基础。具体事宜尚需根据审计、评估、尽职调查结果进一步协商谈判。正式合作协议,还将依照《股票上市规则》、公司《章程》等的规定,经决策程序审议。
(三)该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、合作方的基本情况
1、企业名称:桂林商源植物制品有限公司
2、企业性质:有限责任公司(外商合资)
3、注册地:桂林灵川八里街开发区
4、注册日期:2003年10月23日
5、主要办公地点:广西省桂林市八里街开发区灵川大道33号
6、法定代表人:詹姆斯 周
7、注册资本:捌万美元整
8、经营范围:生产、销售植物脱水制品(涉及前置许可的项目除外)。(依法须经批准的项目,经相关部门批准后方可开展经营活动。)
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(万美元) |
出资比例 |
|
1 |
詹姆斯 周 |
4.4 |
55% |
|
2 |
周文迪 |
3.6 |
45% |
注:詹姆斯 周和周文迪是夫妻关系。
10、经北京汉根会计师事务所有限公司审计,截至2015年底,桂林商源的资产总额4539.72万元、资产净额4540.68万元,2015年度的营业收入0万元、净利润33.42万元。截至2016年半年度末,桂林商源的资产总额10273.06万元、资产净额4530.29万元,2016年半年度的营业收入0万元、净利润-2.85万元;2016年半年度财务数据未经审计。
三、合作标的基本情况
(一)标的公司的基本情况
1、企业名称:北京慧宝源生物技术有限公司
2、企业性质:有限责任公司(外商投资企业与内资合资)
3、注册地:北京市海淀区开拓路5号A区四层A407、A408室
4、注册日期:2011年07月15日
5、主要办公地点:北京市昌平区生命园路20号院7号楼402室
6、法定代表人:周詹姆斯(与桂林商源的法定代表人詹姆斯 周为同一人)
7、注册资本:8000万元
8、经营范围:技术推广、技术转让、技术咨询、技术服务;医学研究与试验发展;技术进出口。
主要通过其子公司广慧科技开展医药产品的生产和销售业务。广慧科技成立于2013年3月,注册资本20000万元(其中北慧生物占75%),住所:中马钦州产业园区中马大街1号,其新建的生产基地设在中国-马来西亚钦州产业园,占地214.46亩,多个剂型的生产车间已基本建成,待通过GMP认证后可投入生产。广慧科技主要从事医药技术开发研究;医药建设项目投资、咨询;颗粒剂、中药前处理和提取、合剂(口服液)、糖浆剂、酊剂(内服、外用)、搽剂、酒剂、片剂生产、销售;新药技术的引进等。2016年广慧科技通过受让药品相关技术的方式,目前已经拥有以中成药制剂为主的76个药品批文,主要产品有:藿香正气水、十滴水、陈香露白露片、复方珍珠解毒口服液、益肝明目口服液等。公司拥有较强的对外合作及新药研发能力,获得了美国耶鲁大学和佐治亚大学研究基金会股份有限公司的“曲沙他滨”抗癌结构专利、治疗方法和全球商业化开发授权;“克来夫定”抗乙肝病毒的中国商业化开发授权;“克来夫定”抗癌结构专利、治疗方法及抗癌全球商业开发优先权。2016年8月,注射用“曲沙他滨”抗肝癌获得了国家食品药品监督管理局颁发的《药物临床试验批件》(批件号:2016L07060),目前正在进行一期临床试验方案的编制工作。
9、主要股东:
|
序号 |
股东名称 |
出资额(万元) |
出资比例(%) |
|
1 |
桂林商源 |
57,437,300 |
71.80 |
|
2 |
何龙飞 |
10,160,000 |
12.70 |
|
3 |
北京慧宝源企业管理有限公司 |
10,000,000 |
12.50 |
|
4 |
其他14名自然人股东 |
2,402,700 |
3.00 |
注:北京慧宝源企业管理有限公司成立于2010年11月18日,法定代表人是周詹姆斯,注册资本为5000万元(其中:桂林商源占有51%),经营范围:企业管理。
(二)截至2015年年底,北慧生物的资产总额28501.85万元、资产净额4034.73万元,2015年度的营业收入80万元、归属于母公司所有者净利润-537.39万元;截至2016年半年度末,北慧生物的资产总额33963.65万元、资产净额14758.21万元,归属于母公司所有者权益合计10250.11万元。2016年半年度的营业收入631.19万元、归属于母公司所有者净利润63.90万元。以上财务数据经具有证券、期货从业资格的中审华寅五洲会计师事务所审计。
(三)北慧生物最近12个月内的增资情况。
最近12个月内,北慧生物进行了3次增资,分别为:
1、2016年3月,北慧生物的注册资本由1000.00万元增至2016.00万元,由何龙飞以人民币增资5,000.00万元,其中1,016.00万元计入实收资本,3,984.00万元计入资本公积。
2、2016年6月,北慧生物的注册资本由2,016.00万元增至7,759.73万元,由桂林商源植物制品有限公司以货币增资5,743.73万元。
3、2016年6月,北慧生物的注册资本变更为8,000.00万元,由14名自然人股东出资人民币600.675万元。其中240.27万元计入实收资本,360.405万元计入资本公积。
四、合作意向书的主要内容
2016年10月8日,桂林商源(甲方)和尖峰药业(乙方)签订了《合作意向书》,主要条款有:
(一)合作方式
甲拟引入乙方为北慧生物的股东,乙方拟以现金出资以增资扩股、受让股权的方式成为北慧生物的股东,具体比例和方式另行协商。
(二)后续工作安排
1、双方共同成立工作组,对合作事宜进行认证,并开展其他相关工作。
2、聘请审计、评估、法律等相关中介机构,做好财务审计、资产评估、法律尽调等前期准备工作。甲方应积极配合乙方及中介机构的尽职调查工作。
(三)排他事项
除非经乙方书面同意,在本意向书签订后3个月内(简称:排他期),甲方及其控制的任何代表人不能直接或间接寻求与任何第三方就北慧生物、广慧科技的股权事宜进行接洽、磋商、谈判或签署任何协议或意向书(不论该协议或意向书是否对其有约束力),但是,甲方与北慧生物、广慧科技原股东就本意向书所述事项商谈不受前述限制。
(四)其他事项
1、本意向书为双方就合作事宜所达成的初步意向,并作为双方开展工作的基础。为推进合作进程,双方将保持沟通,及时磋商与落实相关事宜。
2、双方将在尽职调查和取得北慧生物、广慧科技原股东认可的基础上,尽快开展具体合作事宜的谈判,并签订相关协议。
3、就双方为本次合作而做工作获取的资料以及本意向书所述事宜,除相关法律、法规或证券监管规定外,如果事先没有得到对方的书面同意,任何一方在任何时候不得为任何其他目的使用或许可他人使用或向第三方披露该等信息。
五、本次合作对公司的影响及风险提示
本次合作是根据公司“合作创新强主业、规范科学求发展”战略方针,是做大做强医药业务的具体实施,如果该项合作能顺利完成,将进一步扩大公司医药主业的规模。
鉴于本次签署的是合作意向书,具体合作事宜尚需在审计、评估、尽职调查的基础上进一步协商谈判,并签订相关协议,还将根据《股票上市规则》、公司《章程》等的规定履行董事会或股东大会的审议程序,该合作是否能够实现存在不确定性;同时,新药研发的周期长、投入大、风险高,北慧生物、广慧科技的新药研发、临床试验结果具有一定的不确定性。
公司将根据合作事项的进度及时披露后续进展情况,敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一六年十月十一日
More information
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31
Jianfeng Pharmaceutical Artificial Niuhuang Project Starts
News from this newspaper Jianfeng Pharmaceutical artificial bezoar technical transformation project recently started construction in Qiubin Factory. Artificial bezoar has the effect of clearing away heat and detoxification, resolving phlegm, and is commonly used in Chinese and Western medicines such as colds, clearing away heat and detoxification. As the vast majority of artificial bezoar-related preparations are national essential drugs, with the further implementation of the medical reform policy, the downstream industry of artificial bezoar will enter a new round of business cycle. Jianfeng Pharmaceutical has many years of experience in artificial bezoar production. The technological transformation project will use the existing workshop structure, public works and operators of Qiubin Factory to achieve an annual production capacity of 100 tons of artificial bezoar by adding production equipment such as double cone rotary vacuum drying, horizontal ball mill pulverizer unit, hopper and hoist, closed screening system, and upgrading some public systems. According to the project implementation plan, the project will complete the civil engineering in May. Complete the commissioning, testing and verification of equipment and facilities in July, with trial production conditions; Strive to complete the on-site inspection of GMP certification before the end of December. At present, the factory buildings in Qiubin are vacated and the site is cleaned up. It is understood that the production of natural bezoar is very small, the price is extremely high, and the market rarely provides it. As a biochemical API, artificial bezoar has fewer manufacturers. In the past, due to relatively loose supervision, the testing methods of raw materials and finished products are relatively simple, the quality control indicators are not perfect, and the quality of products on the market is uneven. It is imperative to improve the quality standards. To this end, the State Food and Drug Administration issued the "Biochemical Drug GMP Quality Management Practice (Draft for Comment)" at the end of 2016, which was implemented in March 2017. spike medicine
2020
07-31
Recently, Jianfeng Health has been awarded a number of plaques and certificates by the Department of Science and Technology of Zhejiang Province, the people's Government of Jinhua City, and the Science and Technology Bureau of Jinhua City. They are "Zhejiang Science and Technology small and medium-sized Enterprises", "Jinhua High-tech Enterprises", "Jinhua Agricultural Science and Technology Enterprises", "Jinhua Agricultural Science and Technology Research and Development Center" and so on. According to the relevant requirements, Zhejiang science and technology-based small and medium-sized enterprises must be small and medium-sized enterprises with independent intellectual property rights, proprietary technology or advanced knowledge, engaged in the research, development, production, sales and service of high-tech and its products, and the proportion of enterprises engaged in scientific and technological research and development personnel accounting for no less than 10% of the total number of employees in that year. Since its establishment, Jianfeng Health has attached great importance to the training of scientific and technological personnel, paid attention to the application of its own intellectual property rights, paid attention to product research and development and the protection of intellectual property rights, promoted the application of intellectual property rights, and encouraged employees to invent and create. By the end of 2016, a total of 8 invention patents and 5 appearance patents had been applied, and 1 invention patent and 5 appearance patents had been obtained. High-tech enterprises in Jinhua City must meet the requirements of the ''High-tech Fields Supported by the State, ''and continue to carry out research and development and technological achievements transformation. Their main products (services) have independent intellectual property rights (authorized, registered or accepted). There are certain requirements for the proportion of R & D personnel, the proportion of R & D funds and the income of high-tech products. The acquisition of high-tech enterprises in Jinhua City has laid the foundation for the further declaration of national high-tech enterprises in the future. In the identification of agricultural science and technology enterprises in Jinhua City, the field of peak health technology belongs to the deep processing technology and equipment of agricultural products, Chinese herbal pieces and plant extracts.
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-30
Peak Pharmaceutical was rated as a national intellectual property advantage enterprises
The score ranked first among Jinhua participating enterprises. A few days ago, Peak Pharmaceutical Company was rated as a national intellectual property advantage enterprise. The selection of national intellectual property advantage enterprises is organized by the State Intellectual Property Office. The purpose is to accelerate the formation of a group of Chinese intellectual property leading enterprises with independent intellectual property rights, well-known brands and international competitive advantages, and achieve the development goal of strong intellectual property enterprises. Since Jianfeng Pharmaceutical introduced the GB-T29490-2013 "Enterprise Intellectual Property Management Standard" in 2013, it has been rated as a patent demonstration enterprise in Zhejiang Province in 2013. In 2014, the "Jianfeng" trademark obtained a famous trademark in Zhejiang Province, and the first edition of the "Intellectual Property Manual" was compiled and implemented in 2015. In 2016, it passed the third-party certification of the GB-T29490-2013 "Enterprise Intellectual Property Management Standard". The "Jianfeng" trademark was rated as a well-known trademark by the State Administration of China. In the application and selection of national knowledge by superior enterprises, 52 enterprises in Zhejiang Province won this honor, ranking second in the country in number; Jianfeng Pharmaceutical ranked first among Jinhua participating enterprises. (Zhang Mingyin)
2020
07-31
Group Party Committee to determine the annual work plan
The party Committee of the group company has determined its work ideas and work plan for 2017 a few days ago, and relevant work has been arranged below. In view of the current new political and economic situation and the task of enterprise transformation and development, the general requirements of the Party Committee of the Group Company for 2017 are: to thoroughly study and implement the spirit of the Sixth Plenary Session of the 18th CPC Central Committee and the series of important speeches by General Secretary Xi Jinping, the spirit of the Seventh Party Congress of Jinhua City, to closely revolve around the center of enterprise production, operation and reform and development, and to adhere to scientific development and cross-regional development as the first priority, in order to continue to carry out the study and education of "five stars striving for innovation" and "two learning and one doing", we should highlight the main line of comprehensively and strictly administering the party according to the rules, firmly establish the political consciousness, overall situation consciousness, core consciousness and alignment consciousness of the majority of Party members and cadres, strengthen and improve the party building work in enterprises in the spirit of reform, and strive to improve the scientific, standardized and institutionalized level of Party building work in enterprises, in order to promote the scientific development of the group company, leapfrog development and harmonious development, it provides a strong political, ideological and organizational guarantee. The working idea of the Party Committee of the Group Company in 2017 is to focus on "one center", adhere to "one concept", highlight "three key points" and do a good job in "three constructions". That is: centering on the "one center" of enterprise production, operation and reform and development, we should strive to strengthen the "one concept" of "the organic unity of the party's leadership and the improvement of corporate governance"; to "thoroughly implement the main responsibility of the party committee; continue to carry out the study and education of" two learning and one doing "; and improve the system of party building work" as the "three key points", and focus on "team building and team building
2020
07-31